Author/Authors :
Ranjibar, Farideh Biotechnology Research Center - Venom & Biotherapeutics Molecules Lab - Pasteur Institute of Iran, Tehran , Habibi-Anbouhi, Mahdi National Cell Bank of Iran - Pasteur Institute of Iran, Tehran , Kazemi-Lomedasht, Fatemeh Biotechnology Research Center - Venom & Biotherapeutics Molecules Lab - Pasteur Institute of Iran, Tehran , Aghaee- Bakhtiyari, Hamid Biotechnology Research Center - Mashhad University of Medical Sciences, Mashhad - Department of Medical Biotechnology - Mashhad University of Medical Sciences , Alirahimi, Ehsan Biotechnology Research Center - Venom & Biotherapeutics Molecules Lab - Pasteur Institute of Iran, Tehran , Behdani, Mahdi Biotechnology Research Center - Venom & Biotherapeutics Molecules Lab - Pasteur Institute of Iran, Tehran
Abstract :
Objective(s): Filamentous bacteriophage M13 was genetically engineered to specifically target mammalian cells for gene delivery purpose. Materials and Methods: A vascular endothelial growth factor receptor 2 (VEGFR2)-specific nanobody
was genetically fused to the capsid gene III of M13 bacteriophage (pHEN4/3VGR19). A mammalian expression construct containing Cop-green fluorescent protein (Cop-GFP), as a reporter gene, was amplified by PCR and then sub-cloned in the pHEN4/3VGR19 phagemid. The resulting construct was transfected into 293KDR cell. The recombinant phage was extracted and confirmed and then transduced into VEGFR2 expressing cell (293KDR). Results: Seventy-two hr after transfection, green fluorescence was detected in 30% of the cells. About 1% of the cells which transduced by recombinant phages were able to express GFP. Conclusion: It is hoped that the results from this study will help to find potential vectors to improve
the efficiency of gene delivery. Taken together, we conclude that this newly- introduced vector can be used in cancer researches.
Keywords :
Bacteriophage , Nanobody , Receptor-mediated genetransfer , Targeted-gene delivery , VEGFR2